A study in people with diabetes.

Recruiting now. Registry record last updated February 5, 2026.

Who can join: Adults 18 to 60, have diabetes.
What you take: Check ClinicalTrials.gov for this trial's study groups and what each group receives.
How long it lasts: The full study runs about 2 years.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 1Sponsor David D'Alessio, M.D.Drug Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/minClass OtherSites 1 USEnrollment target 30

What this study is for

Primary condition: Diabetes (DM).

Full scientific study title: Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance..

Who can join

Age18 to 60SexAnyBMIany to 27

Adults 18 to 60, have diabetes. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Age 18-45
Body Mass Index (BMI) \< 27.0
Fasting plasma glucose of ≤ 95 mg/dL or HbA1c value ≤ 5.8% as measured at screening visit

Key exclusion criteria

Active medical disease: e.g. active infectious, inflammatory, neurodegenerative or mental health disorders
Personal history of diabetes or pancreatitis
Personal history of cardiac, gastrointestinal, renal or liver disease
Immediate family history of diabetes
Renal insufficiency (eGFR \< 60 mL/kg/min)

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

North Carolina1 site

Duke Center for Living
Durham, North Carolina
Johanna Johnson, MS919-660-6766johanna.johnson@duke.edu

Follow this trial

We email you if NCT07224334 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Started enrolling: December 30, 2025. Expected completion: December 2027. Last updated on ClinicalTrials.gov: February 5, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.